arrow
C

Christopher P. Mill

university of texas m d anderson cancer center
H指数:33
被引数:3,408

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

更正:基于BET抑制剂的组合,靶向MECOM重排(r) AML中的新型依赖性

Leukemia
IF13.4
2026-03-110
OAAI
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor

通过包含BET蛋白和双重BRG1/BRM抑制剂的组合克服AML细胞中的Menin抑制剂耐药性

Blood
IF23.1
2026-02-260
PRE
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML

BRG1/BRM抑制剂与BET抑制剂或地西他滨的高效联合治疗高风险MECOM重排的急性髓系白血病

2026-01-150
OAAI
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

BET抑制剂为基础的组合,靶向MECOM重排(r) AML中的新型依赖性

Leukemia
IF13.4
2025-12-190
OAAI
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase

基于tasquinimod的联合方案在急变期骨髓增殖性肿瘤(MPN)中的临床前疗效

2025-08-210
OAAI
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1 (vol 13, 53, 2023)

靶向表观遗传共依赖性增强了在MLL1-r或突变NPM1的AML中Menin抑制剂的抗AML疗效(卷13,53,2023)

2025-05-210
OA
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
2022-01-0138
OAAI